UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO\	/AL
OMB Number:	3235-0287
Estimated average bur	den
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * SHERWIN STEPHEN A			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL] 3. Date of Earliest Transaction (Month/Day/Year) 06/11/2004					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner Officer (give title below) Other (specify below)						
(Last) (First) (Middle) CELL GENESYS, INC.,, 500 FORBES BOULEVARD														
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)				_X_ Fo	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
SOUTH	SAN FRA	NCISCO, CA 94	1080							im med by w	iore than one R	eporting r crson		
(Cit	y)	(State)	(Zip)			Tabl	le I - Non-Deri	ative Securities	Acquired, I	Disposed o	of, or Benef	icially Owne	d	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	Execur any			le (A			5. Amount of Se Owned Followin Transaction(s)			Ownership o	. Nature of Indirect Beneficial	
			(Mont	h/Day/Year		Code V A	(A) or (D)	(Instr.	(Instr. 3 and 4)		01 (I	Direct (D) or Indirect (I) (Instr. 4)	Ownership Instr. 4)	
Reminder:			erass or see arreres c	, 0110110101	ily omitted a	ii cotti j								
Reminder:	Report on a	•	Table II				in this for a currer cquired, Dispo	who respond orm are not re tly valid OMB sed of, or Benef	quired to re control nui	espond u mber.				474 (9-02)
1. Title of Derivative Security (Instr. 3)		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transact	5. Nun of Deriva	darran hber tive ties hed	in this for a currer cquired, Dispo	orm are not re tly valid OMB sed of, or Benef evertible securit able and	quired to re control nui	espond umber. d Amount	8. Price of		of 10. Ownersh Form of Derivativ Security: Direct (C or Indirec	11. Natu of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transact	uts, calls, w 5. Nun of Deriva Securit Acquir (A) or Dispos of (D) (Instr.	hber tive ties ed ed 3, 4,	in this for a currer cquired, Disponts, options, con 6. Date Exercis Expiration Date	orm are not re tly valid OMB sed of, or Benef evertible securit able and	quired to recontrol numbers of Underlying Securities	espond umber. d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Ownersh Form of Derivativ Security: Direct (D or Indirec (s) (I)	11. Nature of Indire Benefici ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
SHERWIN STEPHEN A CELL GENESYS, INC., 500 FORBES BOULEVARD SOUTH SAN FRANCISCO, CA 94080	X				

Signatures

James H. Welch (Attorney-In-Fact)	06/11/2004
Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Vest monthly over two years from the date of grant.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, \textit{see} \ Instruction 6 for procedure.$

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.